Phase IV study of respiratory syncytial virus monoclonal antibody therapy in high-risk infants and toddlers

Trial Profile

Phase IV study of respiratory syncytial virus monoclonal antibody therapy in high-risk infants and toddlers

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 01 Nov 2016

At a glance

  • Drugs Palivizumab (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 01 Nov 2016 Results (n=19235) assessing palivizumab adherence and outcomes in aboriginal versus non-aboriginal children receiving palivizumab in the Canadian Registry of palivizumab (CARESS) database (2005-2014), published in the Pediatric Infectious Disease Journal.
    • 06 Oct 2016 Results (n=1909) assessing differences in respiratory-illness related hospitalization (RIH) and respiratory syncytial virus (RSV) specific infection hospitalization (RSVH) in HSCHD infants receiving palivizumab during the first versus second year of life in the Canadian Registry of palivizumab (CARESS) database (2005-2015), published in the Pediatric Infectious Disease Journal..
    • 07 Jun 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top